120
Participants
Start Date
February 12, 2018
Primary Completion Date
June 28, 2018
Study Completion Date
June 28, 2018
XC221 100 mg
once daily during 3 days.
XC221 200 mg
once daily during 3 days.
Placebo
once daily during 3 days.
Сlinical Hospital №3, Yaroslavl
The Center for Prevention and Fight about AIDS and Infectious Diseases, Saint Petersburg
The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation, Saint Petersburg
Research Institute of Influenza, Saint Petersburg
City Clinical Hospital №40 of Kurortny District, Saint Petersburg
City Clinical Hospital №1 n.a. Semashko, Rostov-on-Don
Kuban State Medical University, Krasnodar
Ryazan State Medical University n.a. Pavlov, Ryazan
Volgograd State Medical University, Clinical site - Infectious Regional Clinical Hospital № 1, Volgograd
City Clinical Hospital №9, Izhevsk
Mordovia State Medical University n.a. N.P.Ogarev, Clinical site - Republic Infectious Clinical Hospital, Saransk
PHARMENTERPRISES LLC
INDUSTRY